Page last updated: 2024-11-10

tauro-24,25-dihydrofusidate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tauro-24,25-dihydrofusidate: affects nasal absorption of insulin in sheep [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035005
MeSH IDM0152293

Synonyms (5)

Synonym
tauro-24,24-dihydrofusidic acid
2-[[(2z)-2-[(3r,4s,5s,8s,9s,10s,11r,13r,14s,16s)-16-acetyl-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17-ylidene]-6-methylheptanoyl]amino]ethanesulfonic acid
64691-66-3
tauro-24,25-dihydrofusidate
vd 1177

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Recombinant human GH (hGH) combined with a permeation enhancer for the nasal mucosa, sodium tauro-24,25-dihydrofusidate (STDHF), was administered intranasally (in) in six patients with classical GH deficiency."( Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
Albertsson-Wikland, K; Diczfalusy, M; Flyg, C; Hedin, L; Olsson, B; Petersson, AS; Rosberg, S, 1993
)
0.51

Bioavailability

ExcerptReferenceRelevance
"Nasal sprays containing different concentrations of the somatostatin analogue octreotide and sodium tauro-24,25-dihydrofusidate (STDHF) as an absorption promoter were evaluated in two consecutive pharmacokinetic studies in healthy volunteers to characterize their bioavailability and local tolerability."( Tolerability and absorption enhancement of intranasally administered octreotide by sodium taurodihydrofusidate in healthy subjects.
Bantle, S; Beglinger, C; Drewe, J; Kissel, T; Rummelt, A, 1992
)
0.5
" Compared with intravenous administration, the mean bioavailability of intranasal insulin was 16."( Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep.
Carey, MC; Dubovi, EJ; Flier, JS; Longenecker, JP; Moses, AC; Silver, RD, 1987
)
0.27

Dosage Studied

ExcerptRelevanceReference
" The in dosing results in a plasma peak of hGH very similar to the physiological endogenous peak."( Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
Albertsson-Wikland, K; Diczfalusy, M; Flyg, C; Hedin, L; Olsson, B; Petersson, AS; Rosberg, S, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (18.18)18.7374
1990's17 (77.27)18.2507
2000's1 (4.55)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.55 (24.57)
Research Supply Index3.18 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.55%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]